Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jorge Cortes

Showing results (461-470 of 713) with videos related to

Pageof 72
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 11, 2006
A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignanciesFrancis Giles, Thomas Fischer, Jorge Cortes, et al.
Blood|May 3, 2002
Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phaseHagop M Kantarjian, Jorge Cortes, Susan O'Brien, et al.
Applied Immunohistochemistry & Molecular Morphology : AIMM|July 7, 2017
New Tool for Monitoring Molecular Response in Patients With Chronic Myeloid LeukemiaTalha Badar, Rajyalakshmi Luthra, Hagop Kantarjian, et al.
Cancer|July 25, 2003
Results of decitabine (5-aza-2'deoxycytidine) therapy in 130 patients with chronic myelogenous leukemiaHagop M Kantarjian, Susan O'Brien, Jorge Cortes, et al.
Blood|June 21, 2013
Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon α-2aAlfonso Quintás-Cardama, Omar Abdel-Wahab, Taghi Manshouri, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 4, 2016
Patient Characteristics and Outcomes in Adolescents and Young Adults (AYA) With Acute Myeloid Leukemia (AML)Naveen Pemmaraju, Hagop Kantarjian, Farhad Ravandi, et al.
Biomarker Research|May 29, 2026
A gene signature derived from leukemia associated macrophages provides a compelling risk stratification for human AML patientsDeedra Nicolet, Ting Zhang, Christopher J Walker, et al.
Leukemia Research|December 31, 2013
Phase I evaluation of XL019, an oral, potent, and selective JAK2 inhibitorSrdan Verstovsek, Constantine S Tam, Martha Wadleigh, et al.
Cancer|October 25, 2011
Prognostic significance of alterations in IDH enzyme isoforms in patients with AML treated with high-dose cytarabine and idarubicinFarhad Ravandi, Keyur Patel, Rajyalakshmi Luthra, et al.
Cancer|October 14, 2004
Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemiaHagop Kantarjian, Deborah Thomas, Susan O'Brien, et al.
Pageof 72

Showing results (461-470 of 713) with videos related to

Sort By:
Pageof 72
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 11, 2006
A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignanciesFrancis Giles, Thomas Fischer, Jorge Cortes, et al.
Blood|May 3, 2002
Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phaseHagop M Kantarjian, Jorge Cortes, Susan O'Brien, et al.
Applied Immunohistochemistry & Molecular Morphology : AIMM|July 7, 2017
New Tool for Monitoring Molecular Response in Patients With Chronic Myeloid LeukemiaTalha Badar, Rajyalakshmi Luthra, Hagop Kantarjian, et al.
Cancer|July 25, 2003
Results of decitabine (5-aza-2'deoxycytidine) therapy in 130 patients with chronic myelogenous leukemiaHagop M Kantarjian, Susan O'Brien, Jorge Cortes, et al.
Blood|June 21, 2013
Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon α-2aAlfonso Quintás-Cardama, Omar Abdel-Wahab, Taghi Manshouri, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 4, 2016
Patient Characteristics and Outcomes in Adolescents and Young Adults (AYA) With Acute Myeloid Leukemia (AML)Naveen Pemmaraju, Hagop Kantarjian, Farhad Ravandi, et al.
Biomarker Research|May 29, 2026
A gene signature derived from leukemia associated macrophages provides a compelling risk stratification for human AML patientsDeedra Nicolet, Ting Zhang, Christopher J Walker, et al.
Leukemia Research|December 31, 2013
Phase I evaluation of XL019, an oral, potent, and selective JAK2 inhibitorSrdan Verstovsek, Constantine S Tam, Martha Wadleigh, et al.
Cancer|October 25, 2011
Prognostic significance of alterations in IDH enzyme isoforms in patients with AML treated with high-dose cytarabine and idarubicinFarhad Ravandi, Keyur Patel, Rajyalakshmi Luthra, et al.
Cancer|October 14, 2004
Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemiaHagop Kantarjian, Deborah Thomas, Susan O'Brien, et al.
Pageof 72